Systemic lupus erythematosus–driven accelerated atherosclerosis: the immune–metabolic–vascular axis and therapeutic implications
Patients with systemic lupus erythematosus (SLE) are at markedly increased risk of premature atherosclerosis (AS) and atherosclerotic cardiovascular disease (ASCVD), and this excess risk is not fully explained by traditional Framingham factors. Increasing evidence suggests that…